Introduction {#s1}
============

Sodium/glucose cotransporter-2 (SGLT2) inhibitors are new class of antidiabetic agents for the treatment of type 2 diabetes \[[@R01]-[@R04]\]. The SGLT2 inhibitor, tofogliflozin, has 2,900-fold greater selectivity for SGLT2 than SGLT1, and shows the highest selectivity of all clinically developed inhibitors \[[@R05]\]. Similar to other SGLT2 inhibitors \[[@R06]\], treatment with tofogliflozin was shown to be associated with a significant reduction in body weight in addition to a hypoglycemic effect \[[@R01], [@R07]-[@R11]\]. To our knowledge, however, there have been no reports on its effect on body weight after withdrawal of this agent. It has been demonstrated that circulating adiponectin levels are lower in obese subjects with high body mass index (BMI), large subcutaneous fat area (SFA) \[[@R12], [@R13]\] and visceral fat area (VFA) \[[@R12]-[@R14]\]. Several studies have shown that high-molecular weight (HMW) adiponectin was a better predictor than total adiponectin for predicting metabolic disease \[[@R15]-[@R17]\]. Studies, including our own, have shown that waist circumference is highly associated with both subcutaneous and visceral fat as measured by computed tomography (CT) \[[@R18], [@R19]\].

Here, we investigated how this agent affects body weight and body composition during treatment and after washout of this agent by measuring HMW adiponectin and waist circumference as well as other metabolic parameters.

Materials and Methods {#s2}
=====================

This study represents a sub-analysis of the test meal study that we reported previously \[[@R01]\], and the detailed methods were described in that previous report. We briefly describe sample collection. This 16-week, single-arm, pilot clinical study focused on the potential mechanism by which body weight changes occurred after a 8-week oral administration of tofogliflozin (20 mg/day) and a subsequent 8-week washout of the agent in 10 Japanese men with type 2 diabetic patients who provided written informed consent. On the morning of the day of examination, study subjects did urination completely and took 100 mL of water at 8 a.m. and then did the second urination right before taking blood sampling at 0 min followed by the oral ingestion of one pack of the cookie consisting of 75 g carbohydrate, 28.5 g fat and 8 g protein for a total of 592 kcal. Subjects spent 10 min taking the cookie with 120 mL of water and took blood and urine sampling at 60 and 120 min. Tofogliflozin administration started from the next day for 8 weeks and then discontinued followed by another 8 weeks of observation without tofogliflozin.

The effectiveness and safety of this drug were investigated. The same test was conducted 8 weeks after withdrawal, and factors correlated with changes in body weight after administration and after withdrawal were examined.

Selection criteria included age of 20 - 75 years and hemoglobin A1c (HbA1c) \< 9.0%.

The exclusion criteria were treatment with SGLT 2 inhibitor within the past 2 months, altered therapy on lipemia and hyperuricemia, other diabetes medications, severe renal dysfunction (estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m^2^), diuretics and a history of cerebral infarction. This work was conducted in accordance with Declaration of Helsinki. Informed consent was obtained from all of the participants.

The institutional review board of Kanazawa Medical University Hospital approved the experimental protocol. This clinical trial was registered with UMIN (registration number: UMIN000015778).

All laboratory tests were conducted by SRL Corporation, Japan. Measurement of the HMW adiponectin was conducted by chemiluminescent enzyme assay (Fujirebio Co., Ltd).

We investigate the correlations between changes in body weight between 0 weeks versus 8 weeks to those in waist circumference or HMW adiponectin. We performed the same analysis between 0 weeks versus 16 weeks. Statistical analyses were performed to determine the significance of changes before and after administration of each measurement item and the amounts of change before administration and after withdrawal. Parameters with a normal distribution are shown as the mean ± standard error and were analyzed by the corresponding *t*-test. Items with a non-normal distribution are shown as the median value (25%, 75%) and were analyzed using Wilcoxon's signed-rank test. Bivariate correlations were determined using Pearson's product moment correlation coefficient. In all analyses, *P* \< 0.05 was taken to indicate statistical significance. This study was conducted based on a doctor-initiated clinical research contract with Kowa Co., Ltd.

Results {#s3}
=======

The patient background characteristics are shown in [Table 1](#T1){ref-type="table"}. The changes in parameters before and after administration of tofogliflozin and after washout are shown in [Table 2](#T2){ref-type="table"}. HbA1c decreased significantly from 6.8% before administration to 6.5% after administration of tofogliflozin. Body weight, waist circumference, HMW adiponectin and serum uric acid levels also improved significantly after administration of tofogliflozin. Significant increases were observed in hematocrit and red blood cell (RBC) after administration, and significant increases were maintained even after withdrawal. The area under the curve (AUC) of urinary glucose after test meal loading showed a significant increase after administration, but urinary volume AUC only tended to increase. Significant differences in all of the markers disappeared after withdrawal of the drug.

###### Patient Background

  ---------------------------------------------------------- --------------
  Number of subjects                                         10
  Age (years)                                                60.9 ± 2.8
  HbA1c (%)                                                  6.8 ± 0.2
  Body weight (kg)                                           75.4 ± 4.1
  BMI (kg/m^2^)                                              26.7 ± 1.1
  Waist circumference (cm)                                   91.7 ± 3.0
  Fasting blood glucose (mg/dL)                              140.8 ± 16.2
  Estimated GFR (mL/min/1.73 m^2^)                           77.3 ± 4.3
  Systolic blood pressure (mm Hg)                            139.9 ± 4.5
  Diastolic blood pressure (mm Hg)                           83.4 ± 1.9
  Presence/absence of antihypertensive agent                 5/5
  Presence/absence of use of hyperlipemia treatment agent    5/5
  Presence/absence of use of hyperuricemia treatment agent   1/9
  ---------------------------------------------------------- --------------

Data are presented as mean ± SEM.

###### Changes in Each Parameter Versus Baseline

                                     Baseline            After treatment     After washout                       
  ---------------------------------- ------------------- ------------------- --------------- ------------------- ------------
  HbA1c (%)                          6.8 ± 0.2           6.5 ± 0.2           -0.3\*          6.9 ± 0.3           0.05
  Fasting blood glucose (mg/dL)      140.8 ± 16.2        111.8 ± 7.9         -29.0           124.5 ± 8.8         -16.3
  Body weight (kg)                   75.4 ± 4.1          73.0 ± 4.2          -2.4\*\*\*      74.0 ± 4.7          -1.4
  Waist circumference (cm)           91.7 ± 3.0          89.3 ± 3.0          -2.4\*\*        90.3 ± 3.8          -1.4
  HMW adiponectin (µg/mL)            1.98 (1.35, 3.30)   2.54 (1.56, 4.08)   0.475\*\*\*     2.66 (1.27, 4.25)   0.205
  Uric acid (mg/dL)                  5.38 ± 0.4          4.61 ± 0.4          -0.77\*\*\*     5.25 ± 0.5          -0.13
  Ht (%)                             43.92 ± 1.1         46.84 ± 0.83        2.92\*\*\*      45.39 ± 1.0         1.47\*\*\*
  RBC (/µL)                          480.4 ± 13.8        510.3 ± 10.28       29.9\*\*\*      492.2 ± 11.3        11.8\*
  ^\#^Urine glucose AUC120 min (g)   3.8 ± 2.5           24.7 ± 4.8          20.9\*\*        1.7 ± 1             -2.1
  ^\#^Urine volume AUC120 min (mL)   224.7 ± 50.2        400.4 ± 73.4        175.7           275.1 ± 98.1        50.4

Data are expressed as mean ± SEM or median (1st, 3rd quartile). \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001 (versus baseline) with paired *t*-test or Wilcoxon's signed-rank tests. ^\#^Urine was collected during 120 min after loading test meal and volume and glucose content were measured \[[@R01]\].

Next, we investigated factors potentially affecting body weight changes after administration or withdraw of tofogliflozin. No significant correlations between body weight change and waist circumference change were observed after 8 weeks of administration, but a strong positive correlation was observed after 8 weeks of withdrawal ([Fig. 1](#F1){ref-type="fig"}). Similarly, no significant correlation was observed between body weight change and HMW adiponectin change after 8 weeks of administration, but a significant inverse correlation was observed after 8 weeks of washout ([Fig. 2](#F2){ref-type="fig"}). We examined the correlations between body weight and hematocrit changes ([Fig. 3](#F3){ref-type="fig"}) and those between body weight and 2-hour urine volume changes ([Fig. 4](#F4){ref-type="fig"}) in the same manner. However, no significant correlation was observed either after 8 weeks of administration or after 8 weeks of washout.
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![Correlation between body weight changes and 120-min urine volume changes from baseline.](jocmr-11-01-035-g004){#F4}

In addition to the analysis regarding 0 - 8 weeks and 0 - 16 weeks, we also conducted same analysis on the correlation of body weight change to waist circumference change (or HMW adiponectin change) during 8 - 16 weeks. There were positive correlations between body weight change and waist circumference change (r = 0.82, P = 0.004), while no correlations were observed between body weight change and HMW adiponectin change (r = -0.22, P = 0.55).

There were no side effects during the study period.

Discussion {#s4}
==========

The main findings of this study were as follows: 1) significant correlations between body weight change and waist circumference change were observed after 8 weeks of washout, which were not seen during treatment with tofogliflozin; 2) significant correlations between body weight change and HMW adiponectin changes were observed after 8 weeks of washout, which were not seen during treatment with tofogliflozin.

SGLT2 inhibitors are novel medications that lower blood glucose by promoting urinary glucose excretion and improving metabolism, showing a number of effects such as weight reduction, lowering of blood pressure, uric acid reduction, etc., in addition to hypoglycemic effects \[[@R01]-[@R04]\]. Initially, it was suggested that calorie loss of about 320 kcal caused by 80 g of urinary glucose per day may be solely responsible for the body weight loss by SGLT2 inhibitors \[[@R20]\]. Other mechanisms for body weight loss were also considered because weight reductions were also observed even when administered to renal dysfunction patients with impaired urine secretion \[[@R21]\]. One suggested mechanism was the effect of decreasing body fluid volume due to the osmotic diuretic effect as a result of accelerated urinary glucose excretion, while another mechanism was suggested to be the promotion of fat decomposition \[[@R22], [@R23]\].

In the present study, after 8 weeks of administration, there were no correlations of body weight change with waist circumference or HMW adiponectin change. In contrast, after 8 weeks of washout, there were significant correlations between body weight change and changes in waist circumference and HMW adiponectin. These results suggested that various factors other than fat loss, most likely body fluid volume reduction, may contribute to body weight reduction after 8 weeks of tofogliflozin administration, while after 8 weeks of washout, fat loss may be the sole factor contributing to weight loss given the previous studies on the relations of body fat accumulation to adiponectin \[[@R12]-[@R17]\] ([Fig. 5](#F5){ref-type="fig"}). Our current finding that during treatment with tofogliflozin there were no correlations of body weight change with HMW adiponectin change is not inconsistent with the recent report by Garvey et al \[[@R24]\] showing that the increase in adiponectin with another SGLT2 inhibitor, canagliflozin, was independent of changes in body weight. Thus, we presume that body weight reductions during treatment with SGLT2 inhibitor are combination of body fluid volume reduction and body fat reduction.

![Proposed chart for changes in body weight and potential body composition after treatment and after washout of tofogliflozin. The mechanism by which body weight reductions caused by tofogliflozin may be due to several factors as well as fat reductions at 8 weeks, but those may be due most likely to fat reductions alone after a subsequent 8 weeks of washout (16 week) of this agent.](jocmr-11-01-035-g005){#F5}

There were no correlations of body weight change to hematocrit or urine volume after either 8 weeks of administration or after 8 weeks of washout.

The limitation of this study is that the sample size was small, there was no control group and that body composition was not directly measured. Further study with larger sample size and with control group is needed to confirm the findings in our present pilot study.

In conclusion, in addition to glycemic control, the SGLT2 inhibitor, tofogliflozin, was confirmed to be useful for decreasing body weight, and this body weight loss effect remained even after discontinuation of the drug. The body weight reduction by tofogliflozin may be due to several factors as well as fat reduction at 8 weeks, but the reduction in body weight is most likely due to fat reduction alone after 8 weeks of washout.
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